Alnylam Pharmaceuticals Inc. (ALNY) is seeking to expand the approved use of Oxlumo for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1, and a decision of the FDA is expected on October 6.Oxlumo, known generically as Lumasiran, is already approved by the FDA for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.Primary hyperoxaluria type 1 (PH1) is an ultra-rare genetic disease characterized by oxalate overproduction in the liver. The excess oxalate results in the buildup of calcium oxalate crystals in the kidneys and urinary tract resulting in painful and recurrent kidney stones and nephrocalcinosis.The drug generated global net product revenues of $15 million for the second quarter ended June 30, 2022, compared to $16 million in the year-ago period.ALNY closed Thursday’s (Sep.29,2022) trading at $209.39, down 0.65%.